文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

荷兰脓毒症的社会成本

Societal costs of sepsis in the Netherlands.
PubMed 文献 · Crit Care · 2024-01-22
一句话结论荷兰脓毒症年疾病负担约57,304个QALY,合并疾病与间接经济负担每年38亿至65亿欧元。

该研究利用既往文献与荷兰统计局数据,估算荷兰脓毒症的年度质量调整生命年(QALY)损失、生产力损失及脓毒症后医疗使用增加,并做敏感性分析给出基线、低、高负担估计。结果显示年疾病负担约57,304(24,398-96,244)个QALY,其中死亡占26,898(23,166-31,577)个QALY,脓毒症后生活质量下降占30,406(1,232-64,667)个QALY。间接经济负担按摩擦成本法为4.161(1.471-6.107)亿欧元,按人力资本法为31(4-57)亿欧元;疾病与间接经济负担合计每年38亿(摩擦成本法)至65亿(人力资本法)欧元。作者认为脓毒症及其并发症给荷兰带来沉重的疾病与间接经济负担,其生产力损失所致间接经济负担可能大于冠心病或卒中,并强调未来需研究预防脓毒症以节省下游成本、减轻经济负担。

要点

  • 荷兰脓毒症年疾病负担约57,304(24,398-96,244)个QALY,其中死亡占26,898(23,166-31,577)个QALY。
  • 脓毒症后生活质量下降占30,406(1,232-64,667)个QALY,是疾病负担的主要组成部分之一。
  • 间接经济负担按摩擦成本法为4.161(1.471-6.107)亿欧元,按人力资本法为31(4-57)亿欧元。
  • 疾病与间接经济负担合计每年38亿(摩擦成本法)至65亿(人力资本法)欧元。
  • 作者认为脓毒症生产力损失所致间接经济负担可能大于冠心病或卒中,并强调未来需研究预防脓毒症以节省下游成本。

适用人群与场景

  • 荷兰脓毒症患者及脓毒症存活者,数据来自既往文献与荷兰统计局。

研究设计与关键结果

  • 研究利用脓毒症患病率、发病率、脓毒症相关死亡、住院、预期寿命、生活质量人群常模、脓毒症后生活质量下降及脓毒症后医疗使用等数据,估算年度QALY、生产力损失和脓毒症后医疗使用增加,并以敏感性分析给出基线、低、高负担估计。
  • 年疾病负担约57,304(24,398-96,244;低-高负担)个QALY;死亡占26,898(23,166-31,577)个QALY,脓毒症后生活质量下降占30,406(1,232-64,667)个QALY。
  • 间接经济负担按摩擦成本法为4.161(1.471-6.107)亿欧元,按人力资本法为31(4-57)亿欧元。
  • 疾病与间接经济负担合计每年38亿(摩擦成本法)至65亿(人力资本法)欧元。

证据类型、等级与局限

  • 证据类型:基于既往文献与荷兰统计局数据的成本估算研究,采用敏感性分析给出基线、低、高负担估计。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为脓毒症及其并发症给荷兰带来沉重的疾病与间接经济负担,其生产力损失所致间接经济负担可能大于冠心病或卒中。
  • 作者认为未来需研究预防脓毒症,以节省下游成本并减轻经济负担。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Sepsis is a life-threatening syndrome characterized by acute loss of organ function due to infection. Sepsis survivors are at risk for long-term comorbidities, have a reduced Quality of Life (QoL), and are prone to increased long-term mortality. The societal impact of sepsis includes its disease burden and indirect economic costs. However, these societal costs of sepsis are not fully understood. This study assessed sepsis's disease-related and indirect economic costs in the Netherlands.

METHODS: Sepsis prevalence, incidence, sepsis-related mortality, hospitalizations, life expectancy, QoL population norms, QoL reduction after sepsis, and healthcare use post-sepsis were obtained from previous literature and Statistics Netherlands. We used these data to estimate annual Quality-adjusted Life Years (QALYs), productivity loss, and increase in healthcare use post-sepsis. A sensitivity analysis was performed to analyze the burden and indirect economic costs of sepsis under alternative assumptions, resulting in a baseline, low, and high estimated burden. The results are presented as a baseline (low-high burden) estimate.

RESULTS: The annual disease burden of sepsis is approximately 57,304 (24,398-96,244; low-high burden) QALYs. Of this, mortality accounts for 26,898 (23,166-31,577) QALYs, QoL decrease post-sepsis accounts for 30,406 (1232-64,667) QALYs. The indirect economic burden, attributed to lost productivity and increased healthcare expenditure, is estimated at €416.1 (147.1-610.7) million utilizing the friction cost approach and €3.1 (0.4-5.7) billion using the human capital method. Cumulatively, the combined disease and indirect economic burdens range from €3.8 billion (friction method) to €6.5 billion (human capital method) annually within the Netherlands.

CONCLUSIONS: Sepsis and its complications pose a substantial disease and indirect economic burden to the Netherlands, with an indirect economic burden due to production loss that is potentially larger than the burden due to coronary heart disease or stroke. Our results emphasize the need for future studies to prevent sepsis, saving downstream costs and decreasing the economic burden.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Luijks ECN, van der Slikke EC, van Zanten ARH, et al. Societal costs of sepsis in the Netherlands. Crit Care. 2024. PMID: 38254226. doi:10.1186/s13054-024-04816-3

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。